TB32048 Syngeneic Model Overview
The TB32048 syngeneic model is a genetically defined murine pancreatic ductal adenocarcinoma (PDAC) system derived from C57BL/6 mice. It originates from a pancreatic tumor that developed in a genetically engineered mouse model carrying mutations in the Kras and Trp53 genes, both of which are hallmark drivers of human PDAC. This model represents an aggressive and desmoplastic form of pancreatic cancer with a strong immunosuppressive tumor microenvironment, providing a robust preclinical platform for immunotherapy and combination therapy development.
When implanted orthotopically or subcutaneously into C57BL/6 mice, TB32048 cells form rapidly growing, fibrotic tumors with reproducible kinetics and defined histopathology. The tumors closely resemble human pancreatic ductal adenocarcinoma in both morphology and immune composition. Due to its genetic similarity to human PDAC and responsiveness to combination regimens, the TB32048 model is increasingly used in translational research investigating immune checkpoint blockade, stromal remodeling, and resistance to targeted therapy.
Request a Custom Quote for TB32048 Syngeneic ModelBiological and Molecular Characteristics
The TB32048 cell line was established from a pancreatic tumor arising in a genetically engineered C57BL/6 mouse model harboring activating mutations in Kras and loss-of-function mutations in Trp53. These oncogenic alterations drive constitutive MAPK and PI3K pathway signaling, leading to aggressive tumor growth, epithelial–mesenchymal transition, and immune suppression. TB32048 cells display an epithelial morphology and form compact, poorly differentiated tumors with pronounced desmoplasia.
At the molecular level, TB32048 tumors exhibit elevated expression of transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs), contributing to fibroblast activation, angiogenesis, and extracellular matrix deposition. The tumor microenvironment contains abundant macrophages, myeloid-derived suppressor cells (MDSCs), and cancer-associated fibroblasts, accompanied by sparse T-cell infiltration. This complex stromal and immune network mirrors the immune-excluded phenotype of advanced human pancreatic cancer.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Kras/Trp53-mutant pancreatic ductal adenocarcinoma (mouse) |
| Histological type | Poorly differentiated adenocarcinoma |
| Inoculation route | Orthotopic (pancreatic) or subcutaneous |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–6 days in vivo |
| Metastatic potential | Moderate; local invasion with occasional liver involvement |
| Immunophenotype | Immune-cold, fibroblast- and macrophage-rich stroma |
| Common applications | Immunotherapy, stromal modulation, combination treatment studies |
In Vivo Model Development and Tumorigenicity
The TB32048 syngeneic model can be established by either orthotopic implantation of tumor cells into the pancreas or subcutaneous injection for external tumor monitoring. Orthotopic implantation generates highly desmoplastic tumors with strong local invasion and regional lymph node involvement, accurately replicating the clinical features of human PDAC. Subcutaneous inoculation provides a more accessible system for quantitative tumor measurement and therapeutic testing.
Tumor development occurs within 7–10 days following implantation, with steady progression and high reproducibility. TB32048 tumors are moderately aggressive and display a dense fibrotic capsule that restricts immune infiltration, creating a microenvironment resistant to monotherapy with checkpoint inhibitors. This model’s immune exclusion and stromal barrier properties make it particularly valuable for evaluating novel therapeutic combinations that enhance immune access and overcome stromal resistance in pancreatic cancer.
Request a Custom Quote for TB32048 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of TB32048 tumors reveals disorganized glandular structures composed of epithelial cells with high nuclear atypia and desmoplastic stroma rich in fibroblasts and collagen. Necrosis is minimal, while peritumoral fibrosis and inflammation are prominent. The architecture is consistent with poorly differentiated pancreatic adenocarcinoma and recapitulates the hallmark features of human PDAC.
Immunohistochemical staining demonstrates strong cytokeratin expression, confirming epithelial origin, and high Ki-67 positivity, indicative of active proliferation. The stromal compartment exhibits abundant alpha-smooth muscle actin (α-SMA) expression, consistent with activated fibroblasts. CD3 and CD8 staining show limited T-cell infiltration, while F4/80 and CD11b staining highlight a dominant population of macrophages and myeloid-derived suppressor cells. PD-L1 expression is variable but increases upon exposure to interferon signaling or combination immunotherapy. The histological features of TB32048 tumors reflect the immunologically suppressive, fibrotic nature of pancreatic cancer.
Preclinical Applications and Drug Response
The TB32048 syngeneic model serves as a translationally relevant platform for testing therapeutic strategies targeting pancreatic cancer’s stromal and immune components. Due to its Kras and Trp53 mutations, the model is resistant to monotherapy with immune checkpoint inhibitors but shows improved outcomes when treated with combination regimens. Studies combining PD-1 blockade with TGF-beta inhibition, CXCR4 antagonists, or fibroblast-targeting agents have demonstrated enhanced immune cell infiltration and reduced stromal density.
Chemotherapeutic backbones such as gemcitabine or nab-paclitaxel have been successfully integrated with immunotherapy in this system, producing additive or synergistic effects. The TB32048 model is also widely used for evaluating radiation–immunotherapy combinations and for testing small molecules that modulate macrophage polarization and fibroblast activity. Its genetic similarity to human PDAC and realistic tumor microenvironment make it one of the most clinically relevant syngeneic models for preclinical pancreatic cancer research.
Request This Model
To request the TB32048 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for TB32048 Syngeneic Model